Midatech Survival Plan Scuppered By Shareholders
Investors Unconvinced About Proposed Bioasis Merger
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.
You may also be interested in...
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
The board has resigned at the crisis-hit Norwegian firm after shareholders voted against a reverse merger with APIM Therapeutics.
UK-based Midatech will use money from its US divestment to ramp up R&D efforts and progress its key oncology product MTD201, which has a favorable clinical profile versus Novartis' blockbuster Sandostatin LAR, the biotech's CEO tells Scrip.